Clinical trials · Chicago, IL
Leukemia clinical trials in Chicago
We’re tracking 94 recruiting leukemia studies with a site in or near Chicago — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Chicago
- NCT06366789RecruitingPhase 1
Testing a new drug for AML with FLT3 or spliceosome mutations
This trial tests a new drug called ZE46-0134 for adults with AML that has a specific gene change (FLT3 or spliceosome mutation) and hasn't been controlled by prior treatment. It aims to find the right dose and see if it can help stop the leukemia from growing.
Chicago, IllinoisAges 18 years+ - NCT06943872RecruitingPhase 3
Comparing new treatments for relapsed CLL or SLL
This study tests a combination of sonrotoclax plus obinutuzumab or rituximab versus the current standard venetoclax plus rituximab for people whose CLL or SLL has come back or not responded to previous treatment. The goal is to see which approach helps keep the cancer from growing longer.
Chicago, IllinoisAges 18 years+ - NCT07321652RecruitingPhase 3
Sonrotoclax plus zanubrutinib for untreated CLL or SLL
This trial tests whether adding a new drug, sonrotoclax, to the standard treatment zanubrutinib works better for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who haven't had treatment before. It's for patients aged 65 and older who need therapy due to symptoms or blood cell issues.
Chicago, IllinoisAges 65 years+ - NCT06484062RecruitingPhase 1
Testing cirtuvivint alone and with ASTX727 for leukemia and MDS
This trial tests a new drug called cirtuvivint, given alone or with another drug (ASTX727), for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that has come back or not responded to treatment, and for people with high-risk MDS who have not been treated before. The goal is to see if these combinations work better than current options.
Chicago, IllinoisAges 18 years+ - NCT06917911RecruitingPhase 2
Testing two drug additions to standard chemotherapy for a type of acute myeloid leukemia
This trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) respond better. It may improve chances of remission.
Chicago, IllinoisAges 18–59 - NCT06852222RecruitingPhase 3
Study of bleximenib, venetoclax, and azacitidine for newly diagnosed AML
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
Chicago, IllinoisAges 18 years+ - NCT04836390Enrolling by invitationPhase 2
Donor immune cell treatment after transplant for high-risk AML
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
Chicago, IllinoisAges birth–25 years - NCT07277231RecruitingPhase 3
Comparing two drug combinations for untreated CLL
This trial tests a new combination of drugs (sonrotoclax plus zanubrutinib) against another standard combination (venetoclax plus acalabrutinib) for people with chronic lymphocytic leukemia (CLL) who have not had treatment before. The goal is to see which combination works better.
Chicago, IllinoisAges 18 years+ - NCT05745285Recruiting
LLS care support program for blood cancer patients
This study looks at whether LLS services and support improve outcomes and the day-to-day experience of care for people with leukemia, lymphoma, myeloma, MDS, or MPN. It’s mainly about matching you to the right support and following your progress for 6 months.
Chicago, IllinoisAges 18 years+ - NCT07294677RecruitingPhase 1/Phase 2
Study of capivasertib, venetoclax, and low-intensity chemo for ALL/LBL
This trial tests a combination of targeted drugs (capivasertib and venetoclax) with a gentle form of chemotherapy for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or has not responded to previous treatment. The goal is to see if this approach is safe and effective.
Chicago, IllinoisAges 18 years+ - NCT05865301Recruiting
Outcomes after approved immunotherapy for young blood cancer patients
This study looks at the real-world results of treating certain B-cell blood cancers in children and young adults with commercially available immunotherapy. It may help doctors better understand how these treatments work for patients after relapse or when they need additional therapy.
Chicago, IllinoisAges Up to 26 years - NCT04996875RecruitingPhase 2
Bezuclastinib for advanced mast cell disease
This Phase 2 study tests bezuclastinib, a targeted medicine, in people with advanced systemic mastocytosis (including certain advanced forms with blood cancers). It aims to shrink measurable disease and improve symptoms, while helping people who may also need treatment for an associated blood cancer.
Chicago, IllinoisAges 18 years+ - NCT06423911RecruitingPhase 3
Study of olverembatinib for people with chronic phase CML
This study tests a new targeted drug called olverembatinib for people with chronic myeloid leukemia (CML) that has stopped responding to other treatments. It aims to see if the drug can control the leukemia with fewer side effects.
Chicago, IllinoisAges 18 years+ - NCT03150693RecruitingPhase 3
New treatment for young adults with CD22-positive ALL
This Phase 3 trial tests adding inotuzumab ozogamicin to standard chemotherapy for newly diagnosed CD22-positive B-cell acute lymphoblastic leukemia (ALL). It may help more patients achieve remission and reduce the risk of the leukemia coming back, while also checking safety and tolerability.
Chicago, IllinoisAges 18–39 - NCT05955261RecruitingPhase 2
Study of adding venetoclax to standard chemotherapy for pediatric AML
This trial tests a new combination of a targeted pill (venetoclax) with standard chemotherapy for children and young adults with acute myeloid leukemia (AML). The hope is that adding venetoclax will improve how well the chemo works and reduce the chance of the leukemia coming back.
Chicago, IllinoisAges 4 weeks–21 years - NCT05978141Recruiting
T-cell lymphoma registry study
This study creates a registry for people with certain T-cell or NK-cell lymphomas. It collects health information and tumor samples to learn more about these diseases and improve future treatments.
Chicago, IllinoisAges Any age - NCT05849662RecruitingPhase 1/Phase 2
Trametinib plus azacitidine for newly diagnosed JMML
This trial studies whether trametinib and azacitidine can control juvenile myelomonocytic leukemia (JMML) soon after diagnosis. It’s designed to test safety and how well the treatment works in children and young adults who meet specific leukemia and genetic criteria.
Chicago, IllinoisAges 1 month–21 years - NCT07022678RecruitingPhase 3
Xylitol dental wipes to reduce infection risk in childhood leukemia
This trial tests whether using xylitol dental wipes can lower the risk of bloodstream infections in children with acute myeloid leukemia (AML) who are receiving chemotherapy. If you or your child have AML and will have at least two cycles of chemo that include cytarabine, this study may help reduce infection risk.
Chicago, IllinoisAges 1–25 - NCT06802315RecruitingPhase 2
Radiation therapy before stem cell transplant for high-risk blood cancers
This trial tests a precise type of radiation called intensity modulated total marrow irradiation before a stem cell transplant. It aims to destroy cancer cells while reducing side effects for patients with high-risk leukemia or myelodysplastic syndrome.
Chicago, IllinoisAges 18–65 - NCT06001788RecruitingPhase 1
Ziftomenib for relapsed or refractory acute myeloid leukemia
This trial tests a new drug combination called ziftomenib for people whose acute myeloid leukemia (AML) has come back or hasn't responded to treatment. Researchers will check how safe it is and what side effects happen.
Chicago, IllinoisAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Chicago, IllinoisAges Any age - NCT03571321RecruitingPhase 1
Ruxolitinib plus chemotherapy for Ph-like B-ALL
This early-phase study tests whether adding ruxolitinib (a targeted medicine) to standard chemotherapy improves outcomes in adolescents and young adults with newly diagnosed Ph-like B-precursor acute lymphoblastic leukemia (ALL). It targets specific genetic features (“JAK-targetable signature”) thought to make the leukemia more responsive to JAK-blocking treatment.
Chicago, IllinoisAges 18–39 - NCT00736749Recruiting
Long-term health check for childhood cancer survivors
This trial tracks the long-term health of people who took part in previous Children's Oncology Group studies. It helps doctors understand the lasting effects of cancer treatment and improve care for survivors.
Chicago, IllinoisAges Any age - NCT07284433RecruitingPhase 1/Phase 2
Donor cell therapy for B-cell blood cancers
This trial tests a new treatment made from donor cells that target two proteins (CD19 and CD20) found on certain blood cancer cells. It may be an option for people whose B-cell lymphoma or chronic lymphocytic leukemia has come back or hasn't responded to at least two prior treatments.
Chicago, IllinoisAges 18 years+
Hear when a new Leukemia trial opens near Chicago, IL
We’ll email you when one opens near Chicago, IL — at most once a week, no account needed, unsubscribe anytime.
Leukemia trials in other cities
Where these studies are running near Chicago
Institutions with a site for the recruiting leukemia studies listed above.
- Ann & Robert H. Lurie Children's Hospital of Chicago · 6 studies
- Northwestern University · 6 studies
- University of Chicago Comprehensive Cancer Center · 4 studies
- Loyola University Medical Center · 3 studies
- University of Illinois · 3 studies
- Illinois Cancer Specialists · 2 studies
- Rush University Medical Center · 2 studies
- UC Comprehensive Cancer Center at Silver Cross · 2 studies
What taking part in a leukemia study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting leukemia studies in Illinois.
Common questions
- Are there leukemia clinical trials near Chicago?
- Yes. We're currently tracking 94 recruiting leukemia studies with a site near Chicago, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a leukemia study near Chicago?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Chicago to take part?
- Not necessarily. These studies have a site near Chicago, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a leukemia trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New leukemia studies open near Chicago regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.